What Acuitive Technologies does

Acuitive Technologies Inc. is a privately held US medical device manufacturer founded in 2014 and headquartered in Allendale, New Jersey, that develops and commercializes orthopedic implants built on a proprietary citrate-based polymer platform called CITREGEN. The CITREGEN technology is a resorbable synthetic biomaterial that releases citrate, calcium, and phosphate during hydrolysis and is metabolized during bone remodeling, designed to overcome the chronic inflammation and inconsistent resorption associated with conventional PLA/PGA-based biodegradable polymers. Acuitive's commercial product portfolio spans five device families: CITREGRAFT (synthetic bioactive bone graft substitute, commercially launched November 2025), CITRELOCK ACL and CITRELOCK Foot & Ankle (soft tissue fixation devices for tendon and ligament reconstruction), CITREFIX (knotless suture anchor), and CITREBRIDGE (investigational 3D-printed rotator cuff interpositional scaffold). The company also operates a research collaboration with Northwestern University (Dr. Guillermo Ameer, CITREGEN co-founder) and has published with the University of Pennsylvania on the CITREBIND concept.

Acuitive monetizes through one-time hardware sales of its orthopedic devices to orthopedic surgeons, sports medicine specialists, hospitals, and ambulatory surgery centers. Pricing is quote-based and not publicly disclosed, and the company runs a hybrid go-to-market combining direct field sales to healthcare providers with an authorized distributor network that recruits via a public inquiry portal on its corporate website. The company markets primarily through its corporate website, LinkedIn presence, press release distribution, and an extensive portfolio of peer-reviewed scientific publications, and has built credibility via FDA 510(k) clearances, a Society for Biomaterials 2022 Technology Innovation and Development Award, and a TERMIS-AM 2022 Innovation/Commercialization Award.

Name

Acuitive Technologies

Legal name

Acuitive Technologies Inc.

Website

https://acuitivetech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Acuitive Technologies is a private US orthopedic medical device manufacturer founded in 2014 that develops CITREGEN citrate-based polymer implants—including bone graft substitutes, interference screws, and suture anchors—for orthopedic and sports medicine surgeons at US hospitals and surgery centers.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair) (HLAHAEAF)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

• Orthopedic medical devices
• Bone graft substitutes
• Citrate biomaterial technology
• Soft tissue fixation
• Sports medicine implants

Headquarters

HQ city

Allendale

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Medical Device Sales: Acuitive Technologies generates revenue through the sale of orthopedic medical devices including bone graft substitutes, soft tissue fixation devices, and suture anchors. The company sells CITREGEN-based products directly to healthcare providers and through distributor networks. Revenue is generated through one-time device purchases for surgical procedures.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Acuitive Technologies manufactures CITREGEN-based orthopedic medical devices, including synthetic bioactive bone graft substitutes (CITREGRAFT), knotless suture anchors (CITREFIX), and soft tissue fixation devices (CITRELOCK ACL and CITRELOCK Foot & Ankle), supported by the investigational CITREBRIDGE rotator cuff scaffold. The products serve orthopedic and sports medicine surgeons performing bone repair, soft tissue fixation, and ACL, foot and ankle, and shoulder reconstruction procedures in hospitals and ambulatory surgery centers.

Product overview

Acuitive Technologies manufactures CITREGEN-based orthopedic devices for various musculoskeletal applications. The core technology platform is CITREGEN, a citrate-based polymer technology that mimics natural bone chemistry. The product portfolio includes CITREGRAFT (synthetic bone graft substitute), CITREBRIDGE (rotator cuff interpositional scaffold), CITRELOCK ACL and Foot & Ankle (soft tissue fixation devices), and CITREFIX (knotless suture anchor). These devices serve orthopedic applications in knee, foot and ankle, shoulder, elbow, and wrist surgeries, all utilizing the proprietary CITREGEN biomaterial for repair, regeneration, and resorption.

Differentiator

Problem solved

Functional benefit

Brands

• CITREGEN: Paradigm-changing synthetic biomaterial platform technology using citrate to metabolically guide tissue regeneration.

Products and services

• CITREGRAFT CITREGRAFT is a synthetic, highly porous, bioactive, and resorbable bone graft substitute designed to fill bony voids within the skeletal system. It is pliable and sponge-like, easily morselized, absorbs up to 5 times its weight in body fluid, and comes in various sizes to support new bone growth. CITREGRAFT binds growth factors BMP-2, TGF-β, and PDGF from Bone Marrow Aspirate to support consistent regenerative signaling. It is intended for orthopedic surgeons treating bone voids from trauma, infection, tumor removal, and general bone void filling.
• CITREBRIDGE CITREBRIDGE is a 3D-printed interpositional scaffold placed between soft tissue and bone as an inlay implant, designed to improve both the biological and mechanical aspects of the transitional tissue between the rotator cuff and bone. It targets orthopedic surgeons performing rotator cuff repair. CITREBRIDGE is currently an investigational device and is not available for sale in the United States.
• CITRELOCK ACL CITRELOCK ACL is a soft tissue fixation device designed as a soft, fluted, self-locking device with a cannula for alignment with surgically prepared sites. Its multi-lead, high-pitch design reduces screw revolutions and prevents tendon laceration or twisting during insertion. CITRELOCK ACL is used for ACL reconstruction procedures by orthopedic sports medicine surgeons.
• CITRELOCK Foot & Ankle CITRELOCK Foot & Ankle is a soft tissue fixation device that enables secure and efficient tendon fixation in foot and ankle surgical procedures. The multi-lead, high-pitch fluted device can be malleted into a bone tunnel without twisting or lacerating tissue by eliminating screw revolutions, and it is available in multiple sizes for versatile foot and ankle use. It is targeted at orthopedic foot and ankle surgeons.
• CITREFIX CITREFIX is a barbed, knotless suture anchor designed to attach soft tissue to bone by passing sutures through a PEEK eyelet located at the tip of the device. It provides durable fixation with strong pull-out strength and consistent fixation performance throughout healing. It is intended for orthopedic surgeons performing soft tissue-to-bone anchoring, including rotator cuff and other tendon repair procedures.

Quantifiable outcome

• In vitro studies demonstrate CITREGRAFT strongly binds key growth factors BMP-2, TGF-β, and PDGF to support consistent regenerative signaling
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• University of PennsylvaniacoreStrategic or Co-development Partner · 1 June 2025Acuitive Technologies collaborated with the University of Pennsylvania to publish research in Advanced Functional Materials detailing the development of a citrate-based, 3D-printed scaffold supporting the CITREBIND concept for controlled orthobiologic delivery. The study demonstrates how the scaffold's engineered anionic surface enables strong protein binding and sustained release for effective bone regeneration with significantly lower BMP-2 doses than clinical practice.
• Northwestern University - Dr. Guillermo A. AmeercoreStrategic or Co-development Partner · 1 January 2021Dr. Guillermo A. Ameer, Daniel Hale Williams Professor of Biomedical Engineering at Northwestern University, is the founder of the CITREGEN technology and serves as a scientific advisor. His research lab pioneered the citrate-based biomaterials that form the foundation of Acuitive's technology platform. The collaboration has produced multiple peer-reviewed publications and enabled the technology transfer from lab to market.
• CÚRAM (Centre for Research in Medical Devices)minorStrategic or Co-development PartnerCollaboration with Ireland-based CÚRAM has demonstrated the scientific potential of the CITREGEN bioactive platform technology to expedite tissue healing and mitigate problems associated with currently marketed biodegradable devices for numerous musculoskeletal applications.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Arthrex: Privately held orthopedic sports medicine leader specializing in suture anchors, interference screws, ACL reconstruction, and rotator cuff repair—the exact niches Acuitive targets with CITREFIX, CITRELOCK, and CITREBRIDGE. Most direct product-line competitor.
• Stryker: Global orthopedic medical device leader with broad sports medicine, soft tissue repair, and trauma fixation portfolios that directly overlap Acuitive's CITRELOCK and CITREFIX product lines. Comparable as the dominant incumbent whose sales reach Acuitive must compete against.
• Smith+Nephew: Global orthopedic and sports medicine company with strong soft tissue repair (HEALICOIL suture anchors, BIOSURE interference screws) and orthobiologics portfolios overlapping Acuitive's CITREFIX and CITREGRAFT lines.
• Zimmer Biomet: Major orthopedic device company with sports medicine, ligament reconstruction, and bone graft substitute offerings. Several Acuitive board members came from companies acquired by Zimmer, making it a direct comparable on both product and talent overlap.
• Johnson & Johnson (DePuy Synthes): Orthopedic trauma, sports medicine, and reconstruction franchise through DePuy Synthes and Mitek Sports Medicine. Directly comparable on suture anchors, interference screws, and ligament reconstruction devices.
• Integra LifeSciences: Regenerative medicine and orthopedic company with collagen-based bone graft substitutes and soft tissue repair products (Tissue Technologies). Comparable to Acuitive's regenerative biomaterial platform and bone graft focus.

Direct peers

• Conmed: Orthopedic sports medicine company selling suture anchors, interference screws, and soft tissue fixation devices directly competing with CITREFIX and CITRELOCK ACL. Mid-size player most comparable in scale and product focus to Acuitive.
• Bioventus: Orthobiologics specialist with bone graft substitutes (Osteoamp, Exponent) and regenerative therapies. Closely comparable to Acuitive's CITREGRAFT synthetic bone graft strategy and orthobiologic delivery ambitions.
• Anika Therapeutics: Orthobiologics and hyaluronic-acid-based regenerative medicine company with bone graft substitute and joint preservation products. Most direct comparable to CITREGRAFT's synthetic bone void filler positioning.
• MiMedx: Regenerative medicine company using placental tissue allografts for orthopedic soft tissue repair and wound care. Comparable emerging competitor in the regenerative biomaterials space adjacent to CITREGEN's metabolic biomaterial platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/acuitive-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acuitive Technologies